18F-FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases

Christopher C. Riedl, Timothy Akhurst, Steven Larson, Stephen F. Stanziale, Scott Tuorto, Amit Bhargava, Hedvig Hricak, David Klimstra, Yuman Fong

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

18F-FDG PET has proven invaluable in the staging of patients with metastatic colorectal cancer. The aim of the current study was to determine whether this biologic scan would correlate with other cellular characteristics and the clinical behavior of tumors. Methods: Ninety patients with resectable colorectal cancer metastatic to the liver underwent 18F-FDG PET before hepatectomy. At surgery, tumors were harvested and prepared for assessment by histology and immunohistochemistry. Expression of Ki67 (a marker for cell proliferation), GLUT1 and GLUT3 (markers for glucose transportation), p53 and p27 (markers for cell cycle control), and BCL-2 (a marker for apoptosis) was assessed by a pathologist who was unaware of the PET results and the clinical outcome. Patients were followed to determine outcome. Survival analysis was performed comparing patient outcome in groups segregated according to standardized uptake values (SUVs) greater or less than 5, 7, or 10. Results: Maximum SUV correlated with GLUT1 (P = 0.03), Ki67 (P = 0.026), and p53 (P = 0.024) but did not correlate with p27, BCL-2, or GLUT3. Survival was significantly longer for patients with a low SUV than for patients with a high SUV, with P values of 0.014, 0.025, and 0.0095 for SUV cutoffs of 5, 7, and 10, respectively. Conclusion: 18F-FDG PET is a biologic scan that predicts prognosis in patients with metastatic colorectal cancer. It is uncertain if this ability is due to cellular glucose metabolism or to a correlation with other cellular characteristics of aggressive tumors.

Original languageEnglish (US)
Pages (from-to)771-775
Number of pages5
JournalJournal of Nuclear Medicine
Volume48
Issue number5
DOIs
StatePublished - May 1 2007

Fingerprint

Fluorodeoxyglucose F18
Neoplasm Metastasis
Mortality
Liver
Colorectal Neoplasms
Glucose
Neoplasms
Hepatectomy
Survival Analysis
Cell Cycle Checkpoints
Histology
Immunohistochemistry
Cell Proliferation
Apoptosis
Survival

Keywords

  • F-FDG
  • Hepatic metastases
  • Outcome
  • PET
  • Prognostic variables
  • SUV

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

18F-FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases. / Riedl, Christopher C.; Akhurst, Timothy; Larson, Steven; Stanziale, Stephen F.; Tuorto, Scott; Bhargava, Amit; Hricak, Hedvig; Klimstra, David; Fong, Yuman.

In: Journal of Nuclear Medicine, Vol. 48, No. 5, 01.05.2007, p. 771-775.

Research output: Contribution to journalArticle

Riedl, Christopher C. ; Akhurst, Timothy ; Larson, Steven ; Stanziale, Stephen F. ; Tuorto, Scott ; Bhargava, Amit ; Hricak, Hedvig ; Klimstra, David ; Fong, Yuman. / 18F-FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases. In: Journal of Nuclear Medicine. 2007 ; Vol. 48, No. 5. pp. 771-775.
@article{c547b2cd95584a13ac06563c28a36ade,
title = "18F-FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases",
abstract = "18F-FDG PET has proven invaluable in the staging of patients with metastatic colorectal cancer. The aim of the current study was to determine whether this biologic scan would correlate with other cellular characteristics and the clinical behavior of tumors. Methods: Ninety patients with resectable colorectal cancer metastatic to the liver underwent 18F-FDG PET before hepatectomy. At surgery, tumors were harvested and prepared for assessment by histology and immunohistochemistry. Expression of Ki67 (a marker for cell proliferation), GLUT1 and GLUT3 (markers for glucose transportation), p53 and p27 (markers for cell cycle control), and BCL-2 (a marker for apoptosis) was assessed by a pathologist who was unaware of the PET results and the clinical outcome. Patients were followed to determine outcome. Survival analysis was performed comparing patient outcome in groups segregated according to standardized uptake values (SUVs) greater or less than 5, 7, or 10. Results: Maximum SUV correlated with GLUT1 (P = 0.03), Ki67 (P = 0.026), and p53 (P = 0.024) but did not correlate with p27, BCL-2, or GLUT3. Survival was significantly longer for patients with a low SUV than for patients with a high SUV, with P values of 0.014, 0.025, and 0.0095 for SUV cutoffs of 5, 7, and 10, respectively. Conclusion: 18F-FDG PET is a biologic scan that predicts prognosis in patients with metastatic colorectal cancer. It is uncertain if this ability is due to cellular glucose metabolism or to a correlation with other cellular characteristics of aggressive tumors.",
keywords = "F-FDG, Hepatic metastases, Outcome, PET, Prognostic variables, SUV",
author = "Riedl, {Christopher C.} and Timothy Akhurst and Steven Larson and Stanziale, {Stephen F.} and Scott Tuorto and Amit Bhargava and Hedvig Hricak and David Klimstra and Yuman Fong",
year = "2007",
month = "5",
day = "1",
doi = "10.2967/jnumed.106.037291",
language = "English (US)",
volume = "48",
pages = "771--775",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "5",

}

TY - JOUR

T1 - 18F-FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases

AU - Riedl, Christopher C.

AU - Akhurst, Timothy

AU - Larson, Steven

AU - Stanziale, Stephen F.

AU - Tuorto, Scott

AU - Bhargava, Amit

AU - Hricak, Hedvig

AU - Klimstra, David

AU - Fong, Yuman

PY - 2007/5/1

Y1 - 2007/5/1

N2 - 18F-FDG PET has proven invaluable in the staging of patients with metastatic colorectal cancer. The aim of the current study was to determine whether this biologic scan would correlate with other cellular characteristics and the clinical behavior of tumors. Methods: Ninety patients with resectable colorectal cancer metastatic to the liver underwent 18F-FDG PET before hepatectomy. At surgery, tumors were harvested and prepared for assessment by histology and immunohistochemistry. Expression of Ki67 (a marker for cell proliferation), GLUT1 and GLUT3 (markers for glucose transportation), p53 and p27 (markers for cell cycle control), and BCL-2 (a marker for apoptosis) was assessed by a pathologist who was unaware of the PET results and the clinical outcome. Patients were followed to determine outcome. Survival analysis was performed comparing patient outcome in groups segregated according to standardized uptake values (SUVs) greater or less than 5, 7, or 10. Results: Maximum SUV correlated with GLUT1 (P = 0.03), Ki67 (P = 0.026), and p53 (P = 0.024) but did not correlate with p27, BCL-2, or GLUT3. Survival was significantly longer for patients with a low SUV than for patients with a high SUV, with P values of 0.014, 0.025, and 0.0095 for SUV cutoffs of 5, 7, and 10, respectively. Conclusion: 18F-FDG PET is a biologic scan that predicts prognosis in patients with metastatic colorectal cancer. It is uncertain if this ability is due to cellular glucose metabolism or to a correlation with other cellular characteristics of aggressive tumors.

AB - 18F-FDG PET has proven invaluable in the staging of patients with metastatic colorectal cancer. The aim of the current study was to determine whether this biologic scan would correlate with other cellular characteristics and the clinical behavior of tumors. Methods: Ninety patients with resectable colorectal cancer metastatic to the liver underwent 18F-FDG PET before hepatectomy. At surgery, tumors were harvested and prepared for assessment by histology and immunohistochemistry. Expression of Ki67 (a marker for cell proliferation), GLUT1 and GLUT3 (markers for glucose transportation), p53 and p27 (markers for cell cycle control), and BCL-2 (a marker for apoptosis) was assessed by a pathologist who was unaware of the PET results and the clinical outcome. Patients were followed to determine outcome. Survival analysis was performed comparing patient outcome in groups segregated according to standardized uptake values (SUVs) greater or less than 5, 7, or 10. Results: Maximum SUV correlated with GLUT1 (P = 0.03), Ki67 (P = 0.026), and p53 (P = 0.024) but did not correlate with p27, BCL-2, or GLUT3. Survival was significantly longer for patients with a low SUV than for patients with a high SUV, with P values of 0.014, 0.025, and 0.0095 for SUV cutoffs of 5, 7, and 10, respectively. Conclusion: 18F-FDG PET is a biologic scan that predicts prognosis in patients with metastatic colorectal cancer. It is uncertain if this ability is due to cellular glucose metabolism or to a correlation with other cellular characteristics of aggressive tumors.

KW - F-FDG

KW - Hepatic metastases

KW - Outcome

KW - PET

KW - Prognostic variables

KW - SUV

UR - http://www.scopus.com/inward/record.url?scp=34250625327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250625327&partnerID=8YFLogxK

U2 - 10.2967/jnumed.106.037291

DO - 10.2967/jnumed.106.037291

M3 - Article

VL - 48

SP - 771

EP - 775

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 5

ER -